Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings in the company's Ordinary Shares.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The material change reported is the reduction in shareholdings by three PDMRs to meet tax liabilities following the vesting of awards granted in 2010 under the GlaxoSmithKline Share Value Plan. The shares were sold at a price of £14.55 per share on March 1, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the execution of share sales by executives.
Key Facts for Investor Verification
- Transaction Date: March 1, 2013.
- Share Price: £14.55 per share.
- Executives Involved: Mr. R. Connor, Mr. P. Thomson, and Mrs. V. Whyte.
- Shares Sold: 900 shares by each executive.
- Shares Retained: 830 shares by each executive post-transaction.
- Purpose: To meet tax liabilities associated with the vesting of 2010 awards.